Dentsply Sirona (XRAY)
(Delayed Data from NSDQ)
$25.00 USD
-1.12 (-4.29%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $25.01 +0.01 (0.04%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$25.00 USD
-1.12 (-4.29%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $25.01 +0.01 (0.04%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth C Momentum B VGM
Zacks News
Is Walgreens Boots (WBA) Likely to Disappoint in Q4 Earnings?
by Zacks Equity Research
Persistent de-emphasizing of tobacco is hurting growth, which should get reflected in the upcoming quarterly results of Walgreens Boots Alliance (WBA).
What's in Store for Align Technology's (ALGN) Q3 Earnings?
by Zacks Equity Research
We are optimistic that Align Technology's (ALGN) Invisalign product portfolio has shown continued strength in the third quarter.
Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings?
by Zacks Equity Research
Quest Diagnostics (DGX) is likely to have retained its two-pronged agenda to accelerate growth and drive operational excellence in the third quarter.
What's in Store for Edwards Lifesciences' (EW) Q3 Earnings?
by Zacks Equity Research
The recent full-market launch of the HemoSphere platform with the FloTrac System and Acumen Hypotension Predictive Index should reflect in Edwards Lifesciences' (EW) third-quarter results.
Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) has been growing popular with developments in its flagship, market leading device for the treatment of mitral regurgitation, MitraClip.
Can Balanced Segmental Growth Aid Abbott (ABT) Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) is steadily gaining prominence for developments in its flagship, sensor-based continuous glucose monitoring (CGM) system of FreeStyle Libre.
Dental Supplies Industry's Near-Term Outlook Looks Bright
by Sreyoshi Mukherjee
With popular trends of digital dentistry and robotics gaining momentum, near-term prospects of the dental industry look promising.
Stryker Gains From Flagship Mako and Broad Product Spectrum
by Zacks Equity Research
Stryker's (SYK) broad product spectrum cushions the company from any significant sales shortfall.
AngioDynamics (ANGO) Q1 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
AngioDynamics (ANGO) keeps fiscal 2020 revenue guidance intact, slashes EPS view.
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
XRAY vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?
Here's Why You Should Retain Cardinal Health Stock for Now
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
XRAY vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?
Top Analyst Reports for Intel, Adobe & Mondelez
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Adobe Systems (ADBE) and Mondelez International (MDLZ).
Paylocity, Macy's, Henry Schein, DENTSPLY and Patterson Companies highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Paylocity, Macy's, Henry Schein, DENTSPLY and Patterson Companies highlighted as Zacks Bull and Bear of the Day
3 Best Dental Stocks to Keep An Eye On
by Sriparna Ghosal
Dental practice management software helps dental businesses run smoothly by ensuring safe storage and easy access of critical information.
Dentsply (XRAY) Down 2.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
XRAY or COO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
Allscripts' (MDRX) Veradigm Collaborates With Komodo Health
by Zacks Equity Research
Allscripts (MDRX) expects its Veradigm business to drive bookings in 2019.
Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline
by Zacks Equity Research
Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).
FDA OKs Medtronic's Evolut TAVR New Indication for Low Risk
by Zacks Equity Research
With the FDA's expanded indication nod, Medtronic's (MDT) Evolut TAVR platform now comes in handy for treating symptomatic severe aortic stenosis patients across all risk categories.
Here's Why You Should Add Stryker (SYK) to Your Portfolio
by Zacks Equity Research
Stryker (SYK) gains from core segments in the second quarter of 2019.
Here's Why You Should Hold Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian (VAR) raises the revenue guidance for fiscal 2019.
Here's Why You Should Snap Up Baxter International (BAX) Now
by Zacks Equity Research
For 2019, Baxter (BAX) expects adjusted earnings per share within $3.34-$3.40.
XRAY vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?